Evaluating effectiveness of therapy with topical isoniazid in melasma
Phase 2
- Conditions
- melasma.Other melanin hyperpigmentationL81.4
- Registration Number
- IRCT20211125053175N1
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients with minimum age 20 years old to maximum 60 years old
Patients with diagnosed melasma
Exclusion Criteria
Other topical medication users for melasma in the last four weeks
Kubner-positive diseases such as vitiligo
Lactation and pregnancy
Not consent to medical photography
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Melanin content. Timepoint: At the begining of the study (before intervention) and 4, 8 and12 weeks after intervention. Method of measurement: According to Quantitative measurement of erythema and pigmentation of the patient's skin by Swiss made Dermocatch device.;Efficacy. Timepoint: Percentage change in melanin content before intervention and ?12 weeks after intervention. Method of measurement: Quantitative measurement of pigmentation of the patient's skin by Swiss made Dermocatch device.;Erythema content. Timepoint: At the begining of the study (before intervention) and 4, 8 and12 weeks after intervention. Method of measurement: Using Quantitative measurement of erythema and pigmentation of the patient's skin by Swiss made Dermocatch device.
- Secondary Outcome Measures
Name Time Method Erythema. Timepoint: At the begining of the study (before intervention) and 4, 8 and12 weeks after intervention. Method of measurement: By physical examination and classification of the complications severity into mild, moderate and severe.;Scaling. Timepoint: At the begining of the study (before intervention) and 4, 8 and12 weeks after intervention. Method of measurement: By physical examination and classification of the complications severity into mild, moderate and severe.;Burning sensation. Timepoint: At the begining of the study (before intervention) and 4, 8 and12 weeks after intervention. Method of measurement: By physical examination and classification of the complications severity into mild, moderate and severe.;Increased liver enzymes. Timepoint: At the begining of the study (before intervention) and 12 weeks after intervention. Method of measurement: Based on blood test findings.